CoChat

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Background: Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). Methods: Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) groups, respectively). HRQoL endpoints were assessed over 56 weeks using the Headache Impact Test (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). HIT-6 score reductions ≥2.3 and ≥5 denoted between-group minimally important difference and within-patient clinically meaningful response, respectively. Results: A total of 1236 participants (O/O, n = 607; P/O, n = 629) participated in both phases. The DB phase showed significantly reduced HIT-6 and MSQ for onabotulinumtoxinA versus placebo (all p < 0.001). The OL phase showed significantly reduced HIT-6 for O/O versus P/O at weeks 28, 36, and 48, but not 56. All three MSQ domains showed improved HRQoL relative to baseline, but only the role restrictive domain showed a significant difference between O/O and P/O at week 56. Conclusions: Benefits of onabotulinumtoxinA on HRQoL versus baseline persisted throughout the OL phase. Statistical superiority in favor of O/O was demonstrated for HIT-6 through 48 weeks and for MSQ (role restrictive) at 56 weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0333102416652092

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Efficacy of onabotulinumtoxinA vs. placebo on changes in (a) mean change (standard error) in total HIT-6 scorea and (b) percentage of patients with severe or substantial headache impact (HIT-6 score ≥56) at each time pointb. DB: double-blind; HIT-6: 6-item Headache Impact Test; O/O: onabotulinumtoxinA in double-blind phase and open-label phase (n = 688); OL: open-label; P/O: placebo in double-blind phase and onabotulinumtoxinA in open-label phase (n = 696). aHigher total scores indicate greater negative impact. bCategorically, scores 56–59 indicate substantial impact and ≥60 indicate severe headache impact (13). P values for between-treatment comparisons were determined by the Wilcoxon rank-sum test on (a) total HIT-6 (*p < 0.001; †p = 0.002; ‡p = 0.022) and (b) across the four response categories (*p < 0.001; ‡p ≤ 0.02).
Figure 1. Efficacy of onabotulinumtoxinA vs. placebo on changes in (a) mean change (standard error) in total HIT-6 scorea and (b) percentage of patients with severe or substantial headache impact (HIT-6 score ≥56) at each time pointb. DB: double-blind; HIT-6: 6-item Headache Impact Test; O/O: onabotulinumtoxinA in double-blind phase and open-label phase (n = 688); OL: open-label; P/O: placebo in double-blind phase and onabotulinumtoxinA in open-label phase (n = 696). aHigher total scores indicate greater negative impact. bCategorically, scores 56–59 indicate substantial impact and ≥60 indicate severe headache impact (13). P values for between-treatment comparisons were determined by the Wilcoxon rank-sum test on (a) total HIT-6 (*p < 0.001; †p = 0.002; ‡p = 0.022) and (b) across the four response categories (*p < 0.001; ‡p ≤ 0.02).CC BY-NC · PubMed Central
Figure 2. Efficacy of onabotulinumtoxinA vs. placebo on the proportions of patients achieving (a) individual HIT-6 MIDa during DB and OL phases of PREEMPT trials (*p < 0.001; ‡p = 0.002), (b) individual ≥50% reduction in headache days during DB and OL phases of PREEMPT trials (*p < 0.001; ‡p < 0.05), and (c) individual HIT-6 MID and ≥50% reduction in headache days during DB and OL phases of PREEMPT trials (*p < 0.001; †p = 0.002; ‡p < 0.05). HIT-6: 6-item Headache Impact Test; MID: minimally important difference; O/O: onabotulinumtoxinA in double-blind phase and open-label phase (n = 688); P/O: placebo in double-blind phase and onabotulinumtoxinA in open-label phase (n = 696); PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy. aThe MID for the reduction in HIT-6 total score at the patient level is a score reduction ≥5 points, and is considered to be a clinically meaningful response (22). P values for between-treatment comparisons were determined by Pearson’s chi-square or Fisher exact tests if ≥25% of the expected cell counts are <5 ((a) and (b)).
Figure 2. Efficacy of onabotulinumtoxinA vs. placebo on the proportions of patients achieving (a) individual HIT-6 MIDa during DB and OL phases of PREEMPT trials (*p < 0.001; ‡p = 0.002), (b) individual ≥50% reduction in headache days during DB and OL phases of PREEMPT trials (*p < 0.001; ‡p < 0.05), and (c) individual HIT-6 MID and ≥50% reduction in headache days during DB and OL phases of PREEMPT trials (*p < 0.001; †p = 0.002; ‡p < 0.05). HIT-6: 6-item Headache Impact Test; MID: minimally important difference; O/O: onabotulinumtoxinA in double-blind phase and open-label phase (n = 688); P/O: placebo in double-blind phase and onabotulinumtoxinA in open-label phase (n = 696); PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy. aThe MID for the reduction in HIT-6 total score at the patient level is a score reduction ≥5 points, and is considered to be a clinically meaningful response (22). P values for between-treatment comparisons were determined by Pearson’s chi-square or Fisher exact tests if ≥25% of the expected cell counts are <5 ((a) and (b)).CC BY-NC · PubMed Central
Figure 3. Efficacy of onabotulinumtoxinA versus placebo on the MSQ v2.1a by functional domain during DB and OL phases of the PREEMPT trials. (a) Role Function – Restrictive, (b) Role Function – Preventive, and (c) Emotional Function (*p < 0.001; †p < 0.05). BL: baseline; DB: double-blind; MID: minimally important difference; MSQ: Migraine-Specific Quality of Life Questionnaire; O/O: onabotulinumtoxinA in double-blind phase and open-label phase (n = 688); OL: open-label; P/O: placebo in double-blind phase and onabotulinumtoxinA in open-label phase (n = 696); PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy. aDomain scores are calculated as the sum of their item scores, and then transformed to a 0–100 scale in which higher scores indicate better HRQoL (17,18). P values for between-treatment comparisons were determined by the Wilcoxon rank-sum test ((a), (b), and (c)).
Figure 3. Efficacy of onabotulinumtoxinA versus placebo on the MSQ v2.1a by functional domain during DB and OL phases of the PREEMPT trials. (a) Role Function – Restrictive, (b) Role Function – Preventive, and (c) Emotional Function (*p < 0.001; †p < 0.05). BL: baseline; DB: double-blind; MID: minimally important difference; MSQ: Migraine-Specific Quality of Life Questionnaire; O/O: onabotulinumtoxinA in double-blind phase and open-label phase (n = 688); OL: open-label; P/O: placebo in double-blind phase and onabotulinumtoxinA in open-label phase (n = 696); PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy. aDomain scores are calculated as the sum of their item scores, and then transformed to a 0–100 scale in which higher scores indicate better HRQoL (17,18). P values for between-treatment comparisons were determined by the Wilcoxon rank-sum test ((a), (b), and (c)).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Bayliss MS, 2002, The HIT-6™: A user’s guide

Cited by

See all 87

Metadata

Authors
Lipton, R. B., Rosen, N. L., Ailani, J., DeGryse, R. E., Gillard, P. J., & Varon, S. F.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Northwell Health (US)
  • Georgetown University (US)
  • Allergan plc, Irvine, CA, USA
Corresponding author
Lipton, Richard B
Venue
Cephalalgia
Published
2016-06-10
Volume
36
Issue
9
Pages
899-908
ISSN
  • 0333-1024 (ISSN-L)
  • 1468-2982
OpenAlex
W2417058223
Cited by
85
References
29
Citations by year
2026: 2 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 5 · 2021: 6 · 2020: 15 · 2019: 5 · 2018: 16 · 2017: 10 · 2016: 4
FWCI
10.37
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Cephalalgia (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Teva Pharmaceutical Industries
  • National Institutes of Health
  • Allergan
Topics
  • Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
  • Health Sciences › Dentistry › Oral Surgery › Temporomandibular Joint Disorders
  • Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
Keywords
onabotulinumtoxinA, chronic migraine, health-related quality of life, migraine-specific quality of life, HIT-6, Migraine-Specific Quality of Life Questionnaire, migraine prophylaxis, PREEMPT trial, long-term treatment outcomes
MeSH terms
Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Migraine Disorders, Neuromuscular Agents, Treatment Outcome, Botulinum Toxins, Type A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.